Rhapsido in Bangladesh

Rhapsido - overview

Adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamines. It is an Oral BTK inhibitor (tablet, twice daily) approved by the US FDA in 2025 and may be accessible to patients in Bangladesh through a Named Patient Program or personal-import pathway.

Access in Bangladesh

Bangladesh's DGDA accepts named-patient import under personal-use exceptions; volume is lower but pathway exists.

How Reserve Meds coordinates access in Bangladesh

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Bangladesh-specific eligibility.
3. Treating physician in Bangladesh issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Rhapsido from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Bangladesh.

Typical timeline for Bangladesh

End-to-end, most requests are completed in 2-6 weeks. Bangladesh's tier 3 regulatory maturity typically supports longer processing times.

What patients and physicians in Bangladesh ask

• Is the pathway legal in Bangladesh? Yes - it operates under Bangladesh's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Bangladesh able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Rhapsido in Bangladesh

Join the Rhapsido waitlist